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Abstract
Background: Fish oil is known to improve lifestyle-related diseases. These effects occur partly via activation of
PPARs by the n-3 polyunsaturated fatty acids included abundantly in fish oil. We investigated fish oil functions on
glucose and lipid metabolism that are both dependent on and independent of PPARs pathway.
Methods: Mice were fed a diet containing 30 en% beef tallow (B diet) for twelve weeks to induce obesity. The
mice were then divided into two groups which were fed either a B diet or a diet containing 30 en% fish oil
(F diet). Each group was further divided into two groups which were administered PPARa and g antagonists or
vehicle once a day for three weeks.
Results: The F diet groups showed lower triglyceride levels in plasma and liver than the B diet groups, but PPARs
antagonists did not affect the triglyceride levels in either diet groups. The F diet groups also showed improvement
of glucose tolerance compared with the B diet groups. However, PPARs antagonists made glucose tolerance worse
in the F diet group but improved it in the B diet group. Therefore, by the administration of antagonists, glucose
tolerance was inversely regulated between the B and F diets, and hypolipidemic action in the plasma and liver of
the F diet group was not affected.
Conclusion: These results suggest that fish oil decreases lipid levels in plasma and liver via PPARs pathway-
independent mechanism, and that glucose tolerance is inversely regulated by PPARs antagonists under diets
containing different oils.
Background
It is known that fish oil improves lifestyle-related dis-
eases like diabetes and hyperlipidemia [1,2]. It has been
reported that one of the main mechanisms of the effects
is the activation of peroxisome proliferator-activated
receptors (PPARs) by n-3 polyunsaturated fatty acids
found abundantly in fish oil [3]. PPARs are a family of
transcriptional factors that exist in three isoforms:
PPARa, PPARg, and PPARδ [4]. PPARa is abundantly
expressed in liver and is associated with the lipid- and
lipoprotein-lowering properties by up-regulation of fatty
acid oxidation, while PPARg is predominantly expressed
in adipose tissue and generally affects adipocyte differen-
tiation and adipose tissue lipid distribution by induction
of adipogenesis to recruit new small adipocytes [5].
PPAR δ is ubiquitously expressed and affects lipid meta-
bolism and insulin sensitivity [4,6]. However, functional
relationship between fish oil and PPAR δ has not been
well understood.
Fibrates and thiazolidinediones (TZDs) are well known
drugs activating PPARa and PPARg, respectively.
Fibrates activate PPARa and decrease hepatic triglycer-
ide production by increasing fatty acid oxidation in
hyperlipidemic patients [7,8]. TZDs activate PPARg and
increase insulin sensitivity in diabetic patients [9-11].* Correspondence: ntsunoda@josai.ac.jp
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Although these drugs are composed of simple chemi-
cal components, fish oil contains many types of fatty
acids and unknown components. Therefore, fish oil also
exerts its functions through mechanisms that are inde-
pendent of PPARs. For example, the activity of a num-
ber of lipogenic enzymes such as fatty acid synthase
(FAS) and stearoyl-CoA desaturase are conspicuously
decreased by fish oil. It has been reported that these
enzymes expression levels are tightly controlled by sterol
regulatory element binding protein 1 (SREBP1) tran-
scriptional factor [12,13]. Although there has been sev-
eral reports concerning the relationship between PPARs
and fish oil in the glucose and lipid metabolism [14-17],
it is not well understood how PPARs participate in fish
oil functions.
In this study, we investigated a specific and PPARs-
independent pathway of fish oil functions in diet-
induced obese mice using a PPARa and g antagonists
mixture.
Methods
Animals
Female ddY mice were obtained from Saitama Experi-
mental Animals Supply Co. Japan (Tokyo, Japan) at
5 weeks of age. They had free access to a standard diet
pellet (MF; Oriental Yeast, Tokyo, Japan) and water for
1 week to accommodate to the new environment before
the experiments began. The mice were maintained at a
constant temperature of 23 ± 3°C and humidity of 55 ±
10% with a fixed artificial light cycle (12 hour light/dark
cycle). All procedures were approved by the Josai Uni-
versity Animal Care and Use Committee and complied
with the National Institutes of Health’s Guide for the
Care and Use of Laboratory Animals.
Diets
Experimental diets were consisted of 30% fat and 25%
sucrose on a calorie basis. The composition of the diets
was based on the AIN-93G [18] with modifications as
described previously [19]. Beef tallow or fish oil was
used in the diets instead of soybean oil (B diet or F diet,
Table 1).
Casein, sucrose, b-starch, vitamin mixture, mineral
mixture, cellulose powder and beef tallow were pur-
chased from Oriental Yeast (Tokyo, Japan). L-cystine
and t-butylhydroquinone were purchased from Wako
Pure Chemical Industries, Ltd. (Osaka, Japan), and fish
oil was a gift from the NOF CORPORATION (Tokyo,
Japan). The diets were made following a previous proce-
dure [19].
Experimental procedures
The mice were given free access to the MF diet or each
experimental diet and water for all periods. The control
group was fed the MF diet for all periods. Other mice
were fed the B diet for twelve weeks to induce obesity,
and then divided into two groups which were fed either
the B diet or F diet. Each group was further divided into
two groups which were injected with PPARa and g
antagonists mixture or vehicle (B(+), B(-), F(+) and F(-)
groups) once a day for three weeks. One mg/kg body
weight of the PPARa antagonist MK886 (Wako Pure
Chemical Industries, Ltd., Osaka, JAPAN) and 3 mg/kg
body weight of the PPARg antagonist bisphenol-A-digly-
cidyl ether (BADGE; Tocris Cookson Inc., Missouri,
USA) were subcutaneously injected.
MK886 acts as an inhibitor of PPARa through block-
age of the conformational change which is necessary for
PPARa activation [20,21]. BADGE is a competitive inhi-
bitor of ligand of PPARg [16,22]. We ascertained that
MK886 (1 mg/kg body weight) and BADGE (3 mg/kg
body weight) inhibited 60-70% of the expression of acyl-
CoA oxidase (ACO) gene in liver and CD36 gene in
WAT, which were up-regulated by PPARa or g respec-
tively, at 24 h after the single injection of the mixture of
both inhibitors in ddY mice fed the fish oil diet. The
efficacy of each inhibitor in the mixture was the same as
when individually administered (data not shown).
The body weight of the mice was measured once
weekly during the experimental period. The energy
intake was measured at 13 wk. An oral glucose tolerance
test (OGTT) was conducted at 14 wk under a 6-h fast-
ing condition. The mice were killed at 15 wk after 4-h
fast with an intraperitoneal injection of Somnopentyl
(Kyoritsu Seiyaku Corporation, Tokyo, Japan). Blood
samples were collected from the postcaval vein, and the
plasma was separated by centrifugation (9100 × g for
Table 1 Experimental compositions1
B diet F diet
g/100 g diet
Fish oil - 13.0
Beef tallow 13.0 -
Casein 21.5 21.5
Sucrose 26.4 26.4
Corn starch 28.6 28.6
Vitamin mix 2 1.1 1.1
Mineral mix 3 3.8 3.8
Cellurose 5.4 5.4
L-cystine 0.3 0.3
T-butylhydroquinone 0.003 0.003
Energy, kcal/100 g 408.0 404.4
Fat energy ratio, % 29.9 29.3
Sucrose energy ratio, % 25.0 25.2
1 Based on the AIN-93G (30) and modified.
2, 3 Vitamin and mineral mix were based on the AIN-93G formation.
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10 minutes at 4°C). It was stored at -30°C for analyses.
Weight of the liver and parametrial white adipose tissue
(WAT) were measured. Then, the liver was immediately
frozen in liquid nitrogen, and stored at -80°C for ana-
lyses and measurement of lipids and mRNA. Parametrial
white adipose tissue was fixed in freshly prepared 10%
(w/v) buffered formalin for measurement of the adipo-
cyte surface area.
Measurement of food intake
At 13 wk, food intake and fecal weight were measured
[23]. Food intake and fecal weight are shown as the
average for 3 days. The standard error of food intake
was calculated from the variation of daily intake of each
group.
Oral glucose tolerance test (OGTT)
At 14 wk, D-glucose (1 mg/g body weight; Glucose
Injection, DAIICHI SANKYO COMPANY, LTD.,
Tokyo, Japan) was orally administered by a stomach
tube after 6-h fast. Blood samples were obtained by cut-
ting the tail end before and 15, 30, 60 and 120 minutes
after glucose administration. Blood glucose levels were
measured using the glucose analyzer ASCENSIA DEX-
TER ZII (Bayer Health Care, Osaka, Japan). Plasma
insulin levels were measured using an insulin ELISA kit
(Morinaga Institute of Biological Science Inc., Yoko-
hama, Japan).
Measurement of lipid levels in plasma and liver
The TG and TC levels in plasma were measured by col-
orimetric slides using the FUJI DRICHEM analyzer
(DRI-CHEM 3500, FujiFilm Medical Co. Ltd., Tokyo,
Japan).
The liver sections (100-200 mg) were homogenized
in phosphate buffer solution (pH7.4) by a polytron (PT
3100, KINEMATICA, Inc., Littau/Lucerne, Switzer-
land), and crude lipid extracts were obtained by the
method described by Bligh and Dyer [24]. TG levels
were measured using crude lipid samples by the Wako
TG E test kit (Wako Pure Chemical Industries, Ltd.,
Osaka, Japan).
RNA isolation and measurement of mRNA levels by real-
time RT-PCR
Total RNA was extracted from the liver using TRIzol
Reagent (Invitrogen, USA). Quantitative real-time PCR
analysis was performed on 0.5 μg of total RNA with an
iCycler iQ (Bio-Rad Laboratory, Inc., Tokyo, Japan) and
the ABI Prism 7000 thermal cycler (Applied Biosystems,
Tokyo, Japan) using QuantiTect SYBR Green RT-PCR
(QIAGEN, Germany) with gene-specific primers. The
mRNA levels of liver in all groups were represented as
ratios to the mRNA levels in the B (-) group.
Measurement of adipocyte sectional area
Adipose tissue was fixed in freshly prepared 10% (w/v)
buffered formalin, embedded in paraffin, and the sec-
tions were stained with hematoxylin-eosin. Three differ-
ent representative microscopic fields were captured
manually from sections of each animal and quantitated
with an image analysis system (Image J, Wayne Rasband,
NIH). The mean adipocyte area was calculated from
more than 600 cells per mouse in each group.
Statistical analysis
Statistical comparisons of the groups were made by one-
way ANOVA, and each group was compared with the
others by Fisher’s PLSD test (Protected least significant
difference test) (Statview 5.0; SAS Institute Inc., USA).
P values less than 0.05 were considered to indicate sta-
tistical significance. Values are means ± SE.
Results
Energy intake, fecal weight, final body weight and organs
weight
In the B (+) group, energy intake was significantly
increased and fecal weight was also increased compared
with other groups (Table 2). Final body weight and
organs weight were not different in all groups (Table 2).
Effects of fish oil on lipid metabolism under the
administration of PPARs antagonists
Plasma total cholesterol levels and liver triglyceride
accumulation significantly decreased in the F(-) group
compared with the B(-) group (Table 3). Plasma trigly-
ceride levels and total lipid accumulation in the liver
showed a tendency to decrease in the F(-) group com-
pared with the B(-) group. In the presence of PPARs
antagonists, the liver lipid levels slightly increased in the
B(+) group compared with the B(-) group, but did not
change in the F(+) group compared with the F(-) group
in all parameters.
ACO gene expression in the liver significantly
increased in the F(-) group compared with the B(-)
group (Figure 1A). It was significantly suppressed by
PPARs antagonists in the F(+) group (Figure 1A). While,
FAS and SREBP1-c genes expression in the liver
remarkably decreased in the F(-) group compared with
the B(-) group, but there was no change between the F
(-) and F(+) groups (Figure 1B, C). These mRNA levels
slightly increased in the B(+) group compared with the
B(-) group. FAS and SREBP1-c genes expression levels
were compatible with the plasma and liver lipid levels
(Figure 1B, C, Table 3).
OGTT
To investigate the effect of fish oil under the administra-
tion of PPARs antagonists on glucose metabolism, we
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performed OGTT after 2 weeks administration of
PPARs antagonists. HOMA-IR calculated by the blood
glucose levels and the plasma insulin levels at 0 min in
OGTT was decreased by half in the F(-) group com-
pared with the B(-) group, although it was not signifi-
cantly different in both B and F diet groups in the
presence of PPARs antagonists (Figure 2A).
Compared with the B(-) group, the blood glucose
levels at 15 min in OGTT decreased in the F(-) group
(Figure 2B). In the presence of PPARs antagonists, the
blood glucose levels of the B(+) group decreased at all
indicated times compared with the B(-) group, while the
blood glucose levels of the F(+) group remarkably
increased at 0, 15, 30 and 60 min compared with the F
(-) group (Figure 2B). Similarly, in the blood glucose
area under the curves (AUC) between 0 and 30 min, the
B(+) group was significantly decreased compared with
the B(-) group, whereas the F(+) group was significantly
increased compared with the F(-) group (Figure 2D).
The plasma insulin levels at all times in OGTT and
the plasma insulin AUC were decreased in the F(-)
group compared with the B(-) group (Figure 2C, E). In
the presence of PPARs antagonists, there was no effect
on the plasma insulin levels and plasma insulin AUC in
both diet groups (Figure 2C, E).
Adipocyte size
There was no significant difference in the mean sizes of
the adipocytes amomg 4 groups (B(-), B(+), F(-), F(+))
(Figure 3A, B). The distribution of the sizes of the
adipocytes is shown in Figure 3C and 3D. The peak of
distribution in B(-) group was about 10,000 μm2 and
that in F(-) group was about 5,000 μm2. The distribution
of adipocyte sizes in the B(+) group was smaller than
that in the B(-) group. However, the distribution of adi-
pocyte sizes in the F(+) group was larger than that in
the F(-) group.
Discussion
We have investigated fish oil functions independent of
the PPARa and g pathway in diet-induced obese mice
using a PPARa and g antagonists mixture. By the
administration of the antagonists, the hypolipidemic
action in the plasma and liver was not affected. How-
ever, glucose tolerance was inversely regulated by the
antagonists between the B diet and F diet. This study
suggests that PPARs play more important roles in glu-
cose metabolism than lipid metabolism in diet-induced
obese mice treated with a fish oil diet.
Although many previous studies have reported that
fish oil activated PPARs [25-27], it is not well under-
stood how PPARs participate in fish oil functions. The
previous studies have supported the presence of
PPARa-independent pathway in lipid metabolism in
PPARa-defeicent mice or fish oil diet fed mice [14,15].
In our study, triglyceride levels in the plasma and liver
of the F diet groups were decreased compared with the
B diet groups, but PPARs antagonists did not affect tri-
glyceride levels in both B and F diet groups (Table 3).
Thus, it suggests that the main mechanisms of fish oil
Table 2 Energy intake, fecal weight, final body weight and organs weight
MF B(-) B(+) F(-) F(+)
Energy intake (kcal) 11.23 ± 0.87a 10.23 ± 3.27a 12.63 ± 1.21b 10.73 ± 2.06a 10.04 ± 1.66a
Fecal weight (g) 2.81 ± 0.17a 1.01 ± 0.12bc 1.14 ± 0.14b 0.99 ± 0.05bc 0.76 ± 0.04c
Final body weight (g) 33.8 ± 2.7 39.2 ± 2.4 38.4 ± 3.9 40.0 ± 2.2 40.5 ± 2.0
Liver (g) 1.37 ± 0.10 1.51 ± 0.11 1.67 ± 0.16 1.50 ± 0.06 1.58 ± 0.21
WAT (g) 1.34 ± 0.50 2.41 ± 0.44 2.68 ± 0.93 2.56 ± 0.29 2.82 ± 0.86
Gastrocnemius muscle (g) 0.33 ± 0.02 0.26 ± 0.03 0.31 ± 0.02 0.30 ± 0.02 0.32 ± 0.02
B(-): B diet, B(+): B diet + antagonists mixture, F(-): F diet, F(+): F diet + antagonists mixture. Food intake is shown as the average for 3 days. The standard error
of food intake was calculated from the variation of daily intake of each group. Data is shown as mean ± SE (n = 3 - 4). Significance of difference is indicated as
different alphabet: p < 0.05.
Table 3 Lipids levels in plasma and liver at 15 wk
MF B(-) B(+) F(-) F(+)
Plasma
TG (mmol/L) 1.16 ± 0.17a 0.80 ± 0.15ab 0.94 ± 0.13a 0.55 ± 0.04b 0.49 ± 0.05b
TC (mmol/L) 1.62 ± 0.32ab 2.14 ± 0.31b 2.37 ± 0.20b 1.34 ± 0.15a 1.58 ± 0.30ab
Liver
Total lipid (mg/g liver) 42.8 ± 5.5ac 101.2 ± 19.5ab 129.9 ± 40.6b 52.3 ± 9.0ac 35.2 ± 5.5c
TG (mg/g liver) 9.9 ± 1.3a 44.0 ± 9.3b 44.7 ± 8.3b 12.6 ± 1.5a 8.9 ± 1.9a
B(-): B diet, B(+): B diet + antagonists mixture, F(-): F diet, F(+): F diet + antagonists mixture. Data is shown as mean ± SE (n = 3 - 4). Significance of difference is
indicated as different alphabet: p < 0.05.
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functions on lipid metabolism are PPARs-independent
in diet-induced obese mice. In the liver of the F diet
groups, ACO gene expression levels were decreased, and
FAS and SREBP-1c genes expression levels were not
changed in the presence of PPARs antagonists (Figure
1). Therefore, these results indicate that suppression of
fatty acid synthesis is more important than induction of
fatty acid oxidation by fish oil in liver. These observa-
tions indicate that fish oil functions on lipid metabolism
are mainly controlled by SREBP-1c, which regulates
fatty acid synthesis, and the functions are independent
of PPARs. It is reported that a heterodimer with retinoid
X receptor (RXR) and liver X receptor (LXR) activates
the expression of SREBP-1c, whereas a heterodimer with
RXR and PPARa promotes ACO gene expression
[28,29]. Then, it is thought that PPARa suppression by
the antagonist activates SREBP-1c pathway through
induction of RXR/LXR formation. These cross-talks are
possible to induce up-regulation of SREBP-1c and FAS
genes and slight increase of lipid levels in liver in B diet
groups in this study (Table 3 and Figure 1). On the
other hand, it is thought that the F diet directly sup-
pressed fatty acid synthesis by down-regulation of
SREBP1-c and FAS genes. Then our study supports the
importance of PPARa-independent pathway on lipid
metabolism under the F diet.
In contrast, improvement of glucose metabolism by
fish oil was prevented by PPARs antagonists (Figure 2).
This result suggests that PPARs play more important
roles in glucose metabolism in the F diet groups.
Although Neschen et al have examined the association
of PPARa or g to plasma adiponectin levels and insulin
sensitivity in fish oil-fed wild type or PPARa null mice
[16,17], there has been few reports concerning the
Figure 1 Expression of genes in liver. Mice were killed at 15 wk after 4 h fasting. Liver was removed and gene expression levels of acyl-CoA
oxidase (ACO), fatty acid synthase (FAS) and sterol regulatory element binding protein-1c (SREBP-1c) (A, B, C) were measured by real time RT-
PCR. Gene expression levels are indicated as relative levels to those of the B(-) group. Data is shown as mean ± SE (n = 3 - 4). Significance of
difference is indicated as different alphabet: p < 0.05.
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functional relationship between PPARs and fish oil in
glucose metabolism. By the administration of PPARs
antagonists, blood glucose levels in OGTT increased in
the F diet group, but decreased in the B diet group. Sev-
eral reports observed that inhibition of PPARs also
affected plasma insulin levels [30,31]. However, in our
study, PPARs antagonists did not change insulin levels
in OGTT in the F and B diets (Figure 2). These results
find that the roles of PPARs on glucose metabolism are
influenced by dietary oils.
To elucidate the cause of the inverse regulation of
insulin sensitivity by PPARs antagonists in the B and F
diet groups, we observed the sizes of adipocyte. It has
been reported that small adipocytes improved insulin
sensitivity [32-34] and that a diet containing fish oil
decreased the size of adipocyte [35]. In the distribution
Figure 2 Oral glucose tolerance tests (OGTT). After the injection of PPARs inhibitor for two weeks, a glucose solution was administered by
intragastric gavage at a dose of 1 g/kg body weight after 6 h fasting. HOMA-IR calculated by the blood glucose levels and the plasma insulin
levels at 0 min (A). The blood glucose and plasma insulin concentration were measured at 0, 15, 30, 60 and 120 min after glucose administration
(B, C). Glucose area under the curve (G-AUC) and insulin area under the curve (I-AUC) calculated over 30-min periods after oral glucose
administration (D, E). G-AUC and I-AUC are represented as the relative levels to those of the B(-) group. Data is shown as mean ± SE (n = 3 - 4).
Significance of difference is indicated as different alphabet: p < 0.05.
Wakutsu et al. Lipids in Health and Disease 2010, 9:101
http://www.lipidworld.com/content/9/1/101
Page 6 of 9
of the adipocytes, the adipocytes in the F(-) group were
smaller than the B(-) group. In the presence of PPARs
antagonists, the distribution of the adipocytes was
shifted to smaller in the B groups and larger in the F
groups (Figure 3). It has been reported that internal
PPARg mediates adipocyte hypertrophy and insulin
resistance under long term high fat (beef tallow) diet
[36]. Therfore, PPARg antagonist induced small adipo-
cytes by suppression of lipid accumulation inducing adi-
pocyte hypertrophy, and enhanced insulin sensitivity in
the B diet group. On the other hand, administration of
high amount of PPARg agonist also induced adipogen-
esis recruiting small adipocytes from preadipocytes [37].
Therefore, PPARg antagonist inhibited the function of
fish oil as a strong PPARg stimulator, and increased
large adipocytes and induced insulin resistance.
Our results suggest that there is a PPARs-independent
pathway of fish oil functions on lipid metabolism, and
that PPARs play a more important role in glucose meta-
bolism. SREBP-1c inhibited by fish oil is the main
mechanism of lipid level reduction in mice fed fish oil.
It is also possible that PPARs-stimulating drugs as well
as PPARs inhibitors show different or inverse effects
under diets containing different oils.
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